Delving into the Latest Updates on NBM-BMX softgel capsules with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

NBM BMX softgel capsules, NBM-BMX

+ [1]

Target

HDAC8

Action

inhibitors

Mechanism

HDAC8 inhibitors(Histone deacetylase 8 inhibitors)

Therapeutic Areas

NeoplasmsNervous System DiseasesOther Diseases

Active Indication

NeoplasmsAdvanced Malignant Solid NeoplasmGlioblastoma+ [1]

Inactive Indication

Advanced cancer

Originator Organization

NatureWise Biotech & Medicals Corp.

Active Organization

NatureWise Biotech & Medicals Corp.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC23H27NO5

InChIKeySOWOYQPLOHLYEY-NTEUORMPSA-N

CAS Registry1246952-34-0

NBM-BMX is an orally available new chemical entity to inhibit histone deacetylases 8 (HDAC8) activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise. This study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in subjects with advanced solid tumors or combination with the standard of care treatment in subjects with newly diagnosed glioblastoma.

Start Date11 Aug 2023

Sponsor / Collaborator-

IRCT20180610040037N5

/ RecruitingPhase 3IIT

Examining the Effectiveness and Side Effects of Softgel-Encapsulated IMOD in Individuals Living with HIV

Start Date23 Jul 2023

Sponsor / Collaborator

Tehran University of Medical Sciences

NCT03808870

/ CompletedPhase 1

A Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Efficacy of NBM-BMX in Asian Subjects With Advanced Solid Tumors

NBM-BMX is an orally available new chemical entity to inhibit HDAC8 activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise. The objectives of this study are to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in subjects with advanced solid tumors (Arm A) or in combination with the standard of care treatment (i.e., concomitant RT/TMZ followed by adjuvant TMZ) in subjects with newly diagnosed glioblastoma (Arm B).

Start Date28 Dec 2018

Sponsor / Collaborator

NatureWise Biotech & Medicals Corp.

100 Clinical Results associated with NBM-BMX softgel capsules

Login to view more data

100 Translational Medicine associated with NBM-BMX softgel capsules

Login to view more data

100 Patents (Medical) associated with NBM-BMX softgel capsules

Login to view more data

6

Literatures (Medical) associated with NBM-BMX softgel capsules

22 Aug 2024·Journal of Medicinal Chemistry

Natural Derivatives of Selective HDAC8 Inhibitors with Potent in Vivo Antitumor Efficacy against Breast Cancer

Article

Author: Chen, Zhe ; Fang, Jiebin ; Zhang, Ningjing ; Ma, Zhongjun ; Lou, Yijie ; Mao, Churu ; Gong, Xingzhi ; Zhang, Yuxiao ; Ding, Xia ; Chen, Xiaoming ; Ding, Wanjing ; Yan, Feihang

HDAC8 is a therapeutic target with great promise for breast cancer. Here, we reported a novel compound corallorazine D from Nocardiopsis sp. XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. Upon additional modifications of corallorazine D, a candidate compound 5k, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. The selectivity of 5k was at least 439-fold, superior to corallorazine D, confirming the efficacy of our modifications. In an orthotopic mouse model of breast cancer, 5k displayed nearly 4-fold superior antitumor activity than SAHA. Furthermore, 5k triggered antitumor immunity by activating T cells. Treatment with 5k significantly increased the proportion of M1 macrophages and decreased the proportion of M2 macrophages (M1/M2 ratio = 2.67 ± 0.25). 5k represents a promising compound for further investigation as a potential treatment for breast cancer.

01 Dec 2021·European Journal of Sport ScienceQ2 · MEDICINE

Determinant physiological factors of simulated BMX race

Q2 · MEDICINE

Article

Author: Daneshfar, Amin ; Petersen, Carl ; Gahreman, Daniel

AbstractEvaluating the physiological demands of BMX cycling on a track provides coaches with the information required to prescribe more effective training programmes. To determine the relative importance of physiological factors during simulated BMX race, 12 male riders (age 19.2 ± 3.5 years, height 1.76 ± 0.06 m, mass 68.5 ± 4.3 kg) completed a maximum aerobic capacity (V̇O2max) test in a laboratory, and a week later, completed six laps on a BMX track interspersed by 15 min passive recovery. Peak power, immediate post‐lap V̇O2peak, blood lactate, and heart rate were measured in each lap. Peak power to weight ratio was significantly correlated with lap time, however, the strength of this association decreased in each subsequent lap. Mean V̇O2peak was greater than 80% of laboratory‐measured V̇O2max in every lap, indicating a strong contribution of the aerobic energy system during BMX racing. This study also identified that mean blood lactate was significantly associated with lap time, which showed the importance of the anaerobic energy system contribution to BMX race. Despite the short period of pedalling during BMX racing, both aerobic and anaerobic energy systems are important contributors to lap performance. Coaches should consider maximising both anaerobic power and aerobic capacity to improve riders’ overall performance in multiple laps.

01 Jan 2015·Cellular Physiology and Biochemistry

NBM-T-BMX-OS01, an Osthole Derivative, Sensitizes Human Lung Cancer A549 Cells to Cisplatin through AMPK-Dependent Inhibition of ERK and Akt Pathway

Article

Author: Yang, Tian ; Li, Yang ; Ren, Hui ; Zhou, Yue-Fei ; Chen, Tian-Jun ; Ning, Jie-Juan ; Chen, Ming-Wei ; Zhang, Shuo

Background: Drug combination therapies using cisplatin and natural products are common practice in the treatment of human lung cancer. Osthole is a natural compound extracted from a number of medicinal plants and has been shown to exert strong anticancer activities with low toxicity. Methods: In the present study, NBM-T-BMX-OS01 (BMX), derived from the semi-synthesis of osthole, was evaluated in cisplatin treated A549 cells to investigate its effect on cisplatin resistance in human lung cancer. The anticancer effect of BMX were measured by cell viablity‚ colony formation‚ TUNEL staining‚ flow cytometry and cell cycle assay. The fluorescence staining was performed to detect intracellular and mitochondrial reactive oxygen species (ROS) generation. Western blot analysis, antagonists pretreatment and small interfering RNA (siRNA) transfection were used to determine the potential mechanism. Results: It was found that, in comparison with single cisplatin treatment, the combination of BMX and cisplatin resulted in greater efficacy in inhibition of proliferation and colony formation, apoptosis induction and cell cycle arrest. The results of fluorescence staining showed that the combination effect of BMX and cisplatin was due to oxidative stress induced by mitochondrial ROS generation. In addition, BMX significantly attenuated the phosphorylation of ERK and Akt, two important pro-survival kinases. In contrast, BMX inhibited the activation of AMPK, and knockdown of AMPK using specific siRNA partially reversed BMX-induced inhibition of ERK and Akt, as well as its synthetic effects on cisplatin induced anticancer activity in A549 cells. Conclusion: Taken together, this study provides that BMX might modulate cisplatin resistance through AMPK-ERK and AMPK-Akt pathways. These results also support the role of BMX as a potential drug candidate for use in combination with cisplatin in the treatment of human lung cancer.

100 Deals associated with NBM-BMX softgel capsules

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 2	Taiwan Province	-	11 Aug 2023
Glioblastoma	Phase 2	Taiwan Province	-	11 Aug 2023
Neoplasms	Phase 2	China	NatureWise Biotech & Medicals Corp.	24 Aug 2022
Alzheimer Disease	Phase 1	China	NatureWise Biotech & Medicals Corp.	24 Aug 2022
Advanced cancer	Preclinical	United States	NatureWise Biotech & Medicals Corp.	16 Oct 2018